---
canonical_name: HMR Lignans
alternate_names: 7-Hydroxymatairesinol, 7-HMR, HMRlignan, HMR/lignan, Hydroxymatairesinol, Hydroxymatairesinol Potassium Acetate
canonical_topic: HMR Lignans for Health & Longevity
short_topic_lc: hmr_lignans
creation_date: 2026-0804-1953
creator_ai_fullname: Grok 4
---

# HMR Lignans for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/04/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4

**Also known as:** 7-Hydroxymatairesinol, 7-HMR, HMRlignan, HMR/lignan, Hydroxymatairesinol, Hydroxymatairesinol Potassium Acetate


## Motivation

<!-- Motivation written last after all other sections were completed, to reflect the full scope of the review. -->

HMR lignans (7-hydroxymatairesinol) are plant compounds concentrated in the knots of Norway spruce. After ingestion, gut bacteria convert them into enterolactone, a mammalian lignan linked in observational research to hormone balance and antioxidant defenses. Standardized extracts (often sold as HMRlignan) deliver far higher amounts of this specific lignan than ordinary food sources such as whole grains or seeds.

Interest in HMR lignans grew because they raise blood enterolactone efficiently at milligram doses, and a small clinical study reported fewer hot flashes in postmenopausal women. Laboratory and animal work has explored related biological effects, while broader lignan research connects higher enterolactone with better outcomes after menopause. Commercial products are available as dietary supplements in the United States (under the pathway for new supplement ingredients) and under special food-ingredient rules in Europe.

This review examines the human, animal, and laboratory evidence on HMR lignans for health and longevity, covering benefits, risks, practical use, quality considerations, and open research questions.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

High-level overviews and primary sources that place HMR lignans and related enterolactone biology in clinical and practical context.

<!-- Search note: Web and on-site searches (2026-08-04) for "HMR lignan", "hydroxymatairesinol", "HMRlignan", and "enterolactone" were run for Rhonda Patrick/FoundMyFitness, Peter Attia, Andrew Huberman/Huberman Lab, Chris Kresser, and Life Extension Magazine. No dedicated HMR-lignan content was found from Patrick, Attia, Huberman, or Kresser. Life Extension Magazine has multiple lignan/HMRlignan features; one representative article is included. Primary clinical and mechanistic papers and industry-independent scientific reviews complete the set. -->

* [Lignans](https://www.lifeextension.com/magazine/2010/4/lignans) - Life Extension Magazine

  Accessible magazine synthesis of lignan biology, cancer and cardiovascular associations, and practical dietary and supplemental sources, including context relevant to spruce-derived HMR products.

* [Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study](https://pubmed.ncbi.nlm.nih.gov/24606716/) - Udani et al., 2013

  The principal human intervention on standardized 7-HMR (HMRlignan), funded by the ingredient manufacturer Linnea: absorption, enterolactone formation, hot-flash diary outcomes, and short-term safety at 36 and 72 mg/day.

* [The Power of Lignans: Plant Compounds with Multifaceted Health-Promoting Effects](https://pubmed.ncbi.nlm.nih.gov/41002973/) - Burgberger et al., 2025

  Recent narrative review of lignan chemistry, microbiota conversion to enterolignans, and proposed roles in menopausal symptoms, hormone-related cancers, metabolic and cardiovascular health.

* [Antioxidant and antitumor effects of hydroxymatairesinol (HM-3000, HMR), a lignan isolated from the knots of spruce](https://pubmed.ncbi.nlm.nih.gov/12570335/) - Kangas et al., 2002

  Foundational package of in-vitro antioxidant assays, rodent tumor models, early human single-dose tolerability up to 1,350 mg, and pharmacokinetic conversion to enterolactone.

* [7-Hydroxymatairesinol improves body weight, fat and sugar metabolism in C57BJ/6 mice on a high-fat diet](https://pubmed.ncbi.nlm.nih.gov/30105962/) - Biasiotto et al., 2018

  Primary mouse study of purified 7-HMR on diet-induced weight, fat mass, hepatic lipid, and glucose handling—the main preclinical metabolic efficacy package behind later commercial interest.

No dedicated HMR-lignan episodes or articles were identified from Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman, or Chris Kresser as of the search date; priority-expert coverage is therefore absent rather than overlooked. Industry trade summaries of the Udani trial (e.g., Nutritional Outlook) were not used in this section because they fall outside eligible Recommended Reading source types.


## Grokipedia

<!-- Direct browser search of grokipedia.com for "HMR lignan", "hydroxymatairesinol", and "HMRlignan" (2026-08-04) returned a dedicated Hydroxymatairesinol article plus a general Lignan page. -->

* [Hydroxymatairesinol](https://grokipedia.com/page/hydroxymatairesinol)

  Concise encyclopedia-style overview of 7-hydroxymatairesinol chemistry, Norway spruce source, conversion to enterolactone, selected animal efficacy data, commercial dosing ranges, and regulatory notes.


## Examine

<!-- Direct search of examine.com for "hydroxymatairesinol", "HMRlignan", "HMR lignan", and related terms (2026-08-04). No dedicated Examine.com article or supplement monographs for HMR lignans / 7-hydroxymatairesinol were found. Flaxseed and general lignan mentions appear only within other topics. -->

No Examine.com article dedicated to HMR lignans or 7-hydroxymatairesinol was found.


## ConsumerLab

<!-- Direct search of consumerlab.com for "hydroxymatairesinol", "HMRlignan", "HMR lignan", and "spruce lignan" (2026-08-04). No product review or dedicated monographs for HMR lignan supplements were found. ConsumerLab coverage of lignans is limited to flaxseed and seed-oil contexts. -->

No ConsumerLab review dedicated to HMR lignans or 7-hydroxymatairesinol was found.


## Systematic Reviews

No systematic reviews or meta-analyses for HMR Lignans were found on PubMed as of 04 August 2026.


## Mechanism of Action

* **Enterolactone precursor pathway:** Oral 7-hydroxymatairesinol is absorbed rapidly (plasma peak of the parent compound around 1 hour) and is converted by intestinal microbiota into the mammalian lignan enterolactone (ENL), which peaks later (around 24 hours in pharmacokinetic sampling). ENL is the dominant circulating metabolite; minor metabolites include hydroxyenterolactone, matairesinol-related species, and enterodiol.
* **Phytoestrogen / selective estrogen-receptor modulation:** Both 7-HMR and ENL show mild estrogenic activity in estrogen-sensitive MCF-7 breast-cancer cell-line models that is weaker and less potent than estradiol and is reduced by tamoxifen, consistent with estrogen-receptor (ER)–dependent signaling. In animals, high-dose 7-HMR has also displayed weak antiestrogen-like effects (e.g., reduced ovary weight), so net tissue effects may be context-dependent (tissue type, endogenous estrogen status, dose).
* **Antioxidant activity:** 7-HMR scavenges reactive oxygen species and protects lipids in cell-free and cellular assays, often comparing favorably on a molar basis with reference antioxidants such as Trolox.
* **Immunomodulation and anti-inflammatory effects:** In human monocytic (THP-1) cells and neutrophils, 7-HMR reduces lipopolysaccharide-stimulated tumor necrosis factor-alpha (TNF-α; a key inflammatory cytokine) secretion, reactive oxygen species (ROS) production, and interleukin-8 (IL-8) release.
* **Metabolic and adipose signaling (preclinical):** In high-fat-diet mice, purified 7-HMR reduced adiposity and hepatic fat and improved glucose handling, with down-regulation of inflammatory and adipogenic gene programs; metabolites ENL and enterodiol can inhibit adipocyte differentiation in vitro.
* **Pharmacokinetic properties:** Parent 7-HMR appears quickly in plasma (peak near 1 hour in human sampling); most circulating 7-HMR and ENL are conjugated as glucuronides and sulfates via phase-II pathways typical of polyphenols (UDP-glucuronosyltransferases, or UGTs, and sulfotransferases, or SULTs). Effective human supplemental doses used clinically are typically 36–72 mg/day of standardized HMRlignan (the sugar-free lignan form, or aglycone, co-crystallized with potassium acetate, often ≥90% 7-HMR complex). Detailed tissue distribution and terminal plasma half-life of free parent 7-HMR and free ENL in humans are not fully characterized in public literature; conversion efficiency depends on gut microbiota composition.


## Historical Context & Evolution

* **Source discovery:** 7-Hydroxymatairesinol was long known as a wood constituent; late-1990s Finnish work established Norway spruce (*Picea abies*) knots as an exceptionally rich industrial source (lignans can reach double-digit percentages of dry knot mass, with 7-HMR predominant).
* **Enterolactone link:** Early 2000s studies (including Wärri, Saarinen, Kangas and colleagues) showed oral 7-HMR is efficiently metabolized to enterolactone in rodents and humans, positioning it as a concentrated alternative to flax-derived secoisolariciresinol diglucoside (SDG) for raising mammalian lignans.
* **Commercial development:** Linnea SA developed HMRlignan (7-HMR potassium acetate co-crystal) as a standardized dietary ingredient; it was notified as a New Dietary Ingredient in the United States (mid-2000s era) and has been used in finished supplements (including Life Extension formulas) and novel-food–style applications in Europe.
* **Research arc:** Initial focus was chemoprevention (mammary, prostate, intestinal, uterine models) and antioxidant profiling. Later work added immunomodulation, menopausal symptom pharmacokinetics (Udani 2013), and metabolic outcomes in diet-induced obesity models. Large independent outcome trials remain scarce; much of the human clinical signal still rests on one small menopausal study plus broader observational enterolactone epidemiology.


## Expected Benefits

### Low 🟩

#### Reduced Hot Flash Frequency in Postmenopause

In a single-blind, parallel dose-comparison study of 22 postmenopausal women not on hormone therapy (supported by Linnea, the HMRlignan manufacturer), 72 mg/day HMRlignan for 8 weeks was associated with a statistically significant ~50% reduction in mean weekly hot flashes (from 28.0 to 14.3 per week). The 36 mg/day arm raised plasma 7-HMR and enterolactone but did not achieve a comparable, statistically significant symptom effect. The trial was small, lacked a placebo arm, was industry-supported, and used diary outcomes; independent replication is absent.

**Magnitude:** Approximately 50% reduction in weekly hot flash count at 72 mg/day over 8 weeks (n = 22, single-blind, no placebo).

#### Efficient Elevation of Circulating Enterolactone

The same human pharmacokinetic work showed rapid absorption of 7-HMR (peak plasma concentration, or Cmax, about 757 ng/mL at 1 hour at the lower dose sampled) and multi-fold increases in plasma 7-HMR and enterolactone over 8 weeks at both 36 and 72 mg/day. Higher enterolactone is the mechanistic bridge to many observational associations for dietary lignans, so reliable ENL elevation is a documented intermediate benefit of HMR supplementation.

**Magnitude:** Plasma 7-HMR increased ~191% (36 mg/day) to ~1,238% (72 mg/day); enterolactone rose up to ~137–157% from baseline over 8 weeks (Udani et al., 2013).

#### Antioxidant Activity

In cell-free and cellular systems, 7-HMR scavenges superoxide and peroxyl radicals and inhibits lipid peroxidation and low-density lipoprotein oxidation, often outperforming Trolox on a molar basis and matching or exceeding the synthetic preservative antioxidants butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) in selected assays. In vitamin E–deficient mice, high-dose 7-HMR preserved body-weight gain comparably to alpha-tocopherol, supporting in-vivo antioxidant activity. Human clinical antioxidant biomarkers after HMR supplementation are not well established.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Anti-Inflammatory / Immunomodulatory Effects on Innate Immune Cells

In human monocytic THP-1 cells and primary neutrophils, 7-HMR concentration-dependently reduced lipopolysaccharide (LPS)–driven TNF-α secretion, ROS generation, and IL-8 production. These findings support a plausible anti-inflammatory contribution to vascular and systemic aging pathways but remain limited to laboratory (ex-vivo/in-vitro) human cells without corresponding controlled human inflammatory-marker trials of HMR alone, so any clinical anti-inflammatory benefit is still unproven.

#### Breast Cancer Risk and Prognosis Modulation via Enterolactone

Meta-analyses of dietary lignans and circulating enterolactone (not HMR-specific) associate higher lignan exposure with modestly lower postmenopausal breast-cancer risk and, in survivors, lower all-cause and breast-cancer–specific mortality. Premenopausal associations are less favorable or reversed in some analyses. No randomized HMR trial has tested breast-cancer incidence or recurrence.

#### Prostate Cancer Chemoprevention

Dietary 7-HMR reduced tumor engraftment (take rate) and growth of LNCaP human prostate cancer cells implanted as xenografts (human tumor tissue grown in immunodeficient mice) and increased tumor-cell apoptosis. Observational phytoestrogen literature is mixed for prostate cancer. No HMR prostate-cancer outcome trials exist in humans.

#### Metabolic Health (Body Weight, Fat Mass, Glycemia)

In high-fat-diet C57BL/6 mice, purified HMR reduced body weight and fat mass (~11%), cut hepatic lipid accumulation substantially, and improved glucose tolerance and insulin sensitivity with lower inflammatory gene expression in adipose and liver. Human metabolic trials of HMR are lacking.

#### Cardiovascular Protection

Higher circulating enterolactone has been linked in meta-analyses of observational biomarker studies to lower cardiovascular and all-cause mortality. Proposed mechanisms include antioxidant effects, mild estrogen-receptor modulation of vessels, and anti-inflammatory actions. Direct HMR cardiovascular outcome data in humans are absent.

#### Bone and Joint Support

Marketing and secondary literature sometimes cite bone and joint benefits for lignans and HMR, typically via mild estrogen-receptor–related pathways that can influence bone remodeling in other phytoestrogen contexts. The basis is mechanistic analogy and general lignan nutrition commentary rather than controlled HMR densitometry, fracture, or joint-outcome trials. Robust HMR-specific human bone or joint data were not identified, so any such benefit remains unproven.


## Benefit-Modifying Factors

* **Gut microbiota composition:** Conversion of 7-HMR to enterolactone requires a competent lignan-metabolizing microbiome. Antibiotic use, severe dysbiosis (disrupted gut microbial balance), or low fiber intake may blunt ENL formation and thus ENL-dependent effects.
* **Menopausal / estrogen status:** Hot-flash data are limited to postmenopausal women. Observational lignan–breast-cancer associations differ by menopausal status (generally more favorable postmenopause). Premenopausal hormonal context may change net benefit–risk balance.
* **Baseline enterolactone and lignan intake:** Individuals with very low dietary lignan intake may show larger relative ENL increases; those already eating high-lignan diets (flax, sesame, whole grains, berries) may see smaller incremental gains.
* **Sex:** Human HMR symptom data are female-only (postmenopause). Male interest centers on prostate and metabolic preclinical signals; sex-specific dosing guidance is not established.
* **Age:** Older adults are the primary commercial and study population (menopause, prostate risk, cardiovascular risk). Age-related changes in microbiota and estrogen status may modify response; dedicated geriatric trials are lacking.
* **Hormone-sensitive conditions and concurrent endocrine therapy:** Mild ER activity means phytoestrogen supplements such as HMR are a potential interacting agent for people with estrogen-receptor–positive cancers or on selective estrogen-receptor modulators / aromatase inhibitors; published safety data in those settings are limited.


## Potential Risks & Side Effects

### Low 🟥

#### Mild Estrogenic / Antiestrogenic Tissue Effects

In vitro, 7-HMR and enterolactone stimulate estrogen-sensitive breast-cancer cell cycle progression less potently than estradiol; effects are attenuated by tamoxifen. In a 13-week rat dietary toxicity study, high-dose HMRlignan reduced absolute and relative ovary weights and slightly lengthened the estrous cycle, interpreted as weak antiestrogen-like activity, with a no-observed-adverse-effect level (NOAEL) of 160 mg/kg body weight/day. Human trials at 36–72 mg/day for 8 weeks and single doses up to 1,350 mg in healthy men did not report clinically significant hormonal adverse events, but long-term endocrine safety data are limited.

**Magnitude:** NOAEL 160 mg/kg/day in rats (ovary weight); human supplemental doses (~0.5–1 mg/kg) are far lower; clinical hormonal adverse-event rates not quantified beyond short trials reporting good tolerability.

#### Gastrointestinal Intolerance (Uncommon)

Lignan and fiber-rich botanicals can cause bloating, loose stools, or mild abdominal discomfort in sensitive users. Published HMR trials emphasize overall good tolerability and did not highlight a high rate of gastrointestinal (GI) events; incidence remains poorly quantified.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Theoretical Concerns in Hormone-Sensitive Cancer

Because 7-HMR and ENL interact with estrogen-receptor pathways, theoretical risk (or benefit) exists for people with active estrogen-receptor–positive breast cancer or other hormone-dependent tumors. Observational enterolactone data in postmenopausal survivors lean protective, but supplementing isolated HMR has not been tested as adjuvant therapy, and safety or efficacy in oncology settings is not established in controlled trials.

#### Uncertain Long-Term High-Dose Safety in Humans

Subchronic rodent studies and short human exposures support a wide margin of safety at usual supplemental doses (typically 36–72 mg/day for weeks). Multi-year human safety cohorts for high-dose standardized 7-HMR are lacking, so late endocrine, metabolic, or rare adverse effects cannot be ruled out from existing data. The basis for concern is the absence of long-duration controlled follow-up rather than a documented late toxicity signal.


## Risk-Modifying Factors

* **Dose relative to body weight:** Animal ovary-weight effects appeared at high dietary percentages; usual human doses (36–72 mg/day) are orders of magnitude below the rat NOAEL on a mg/kg basis, but higher-than-label chronic intake has not been systematically studied.
* **Estrogen-receptor–positive disease or endocrine therapy:** Concurrent tamoxifen, aromatase inhibitors (e.g., anastrozole, letrozole), or active hormone-sensitive malignancy may alter the risk profile of any phytoestrogen; controlled co-use data are sparse.
* **Sex and reproductive stage:** Premenopausal women, pregnancy, and lactation lack adequate HMR safety data; animal developmental toxicity work exists for regulatory packages, but human pregnancy use is not established.
* **Age and comorbidities:** Older adults with polypharmacy or impaired gut function may experience different ENL conversion and drug–nutrient interactions; data are sparse.
* **Baseline liver and kidney function:** 7-HMR and ENL undergo conjugation and renal/biliary elimination pathways typical of polyphenols; severe hepatic or renal impairment could theoretically alter exposure (not directly studied for HMR).


## Key Interactions & Contraindications

* **Selective estrogen-receptor modulators and aromatase inhibitors (tamoxifen, raloxifene, anastrozole, letrozole, exemestane):** Severity: caution / specialist oversight. Theoretical competition or additive modulation of estrogen pathways. Mitigating action: avoid unsupervised combination during active endocrine therapy.
* **Systemic hormone therapy and hormonal contraceptives:** Severity: caution. Mild phytoestrogenic activity could theoretically modify systemic estrogen signaling. Mitigating action: disclose supplement use to the prescribing clinician; monitor symptom control.
* **Antibiotics and major microbiome disruptors:** Severity: monitor. Reduced conversion of 7-HMR to enterolactone may diminish ENL-dependent effects until microbiota recover. Mitigating action: expect attenuated ENL rise during and shortly after broad-spectrum antibiotics.
* **Other phytoestrogens and high-lignan foods (soy isoflavones, flax SDG, red clover, hop extracts):** Severity: monitor for additive hormonal or GI effects. Mitigating action: account for total phytoestrogen load if combining women’s-health formulas.
* **Anticoagulants / antiplatelets (warfarin, clopidogrel; over-the-counter aspirin and high-dose NSAIDs (nonsteroidal anti-inflammatory drugs) such as ibuprofen):** Severity: low theoretical caution (polyphenol class effect, not HMR-specific bleeding signal). Mitigating action: standard bleeding-risk awareness; no established HMR–warfarin interaction study.
* **Other over-the-counter (OTC) medications:** Severity: generally low. No well-documented HMR-specific interactions with common OTC analgesics, cold remedies, or antacids beyond the anticoagulant/antiplatelet caution for aspirin and NSAIDs. Mitigating action: disclose HMR use when reviewing full medication lists; watch for additive gastrointestinal discomfort if combining multiple botanicals.
* **Populations who should avoid or use only under specialist care:**
  * Pregnancy and lactation (inadequate human data)
  * Active estrogen-receptor–positive breast or gynecologic cancers without oncology approval
  * Children and adolescents (not a studied population; EU novel-food–style limits often exclude young children for related botanicals)
  * Known allergy to spruce/pine-derived materials (rare; theoretical)


## Risk Mitigation Strategies

* **Stay within studied supplemental doses:** Use products providing about 36–72 mg/day 7-HMR (as HMRlignan or equivalent standardized extract), the range used in the postmenopausal human trial and common commercial labels. This keeps exposure far below rodent NOAEL levels and targets the dose with the only human symptom signal.
* **Disclose phytoestrogen use during endocrine therapy:** For anyone on tamoxifen, aromatase inhibitors, or with hormone-sensitive tumors, obtain oncology or endocrinology review before starting—mitigates theoretical ER-pathway interaction risk.
* **Support microbiota conversion:** Maintain dietary fiber and fermented foods when appropriate; avoid expecting full ENL benefits during antibiotic courses—addresses incomplete conversion risk.
* **Start low if GI-sensitive:** Begin at 36 mg/day for 1–2 weeks before increasing to 72 mg/day—reduces chance of mild digestive discomfort.
* **Avoid combining multiple high-dose phytoestrogen products:** Prevents unquantified cumulative hormonal load.
* **Periodic clinical follow-up for long-term users:** Especially postmenopausal users with personal or strong family hormone-sensitive cancer history—supports early detection of unexpected hormonal effects.


## Therapeutic Protocol

* **Standard supplemental approach:** Leading commercial protocols use standardized Norway spruce knot extract providing **36–72 mg/day** of 7-HMR as the potassium acetate co-crystal (HMRlignan-type material, often ≥90% complex). The only human symptom study used 36 mg/day and 72 mg/day for 8 weeks; hot-flash reduction reached significance at 72 mg/day.
* **Competing approaches:** Food-first lignan strategies emphasize ground flaxseed (SDG), sesame, rye, and berries rather than isolated 7-HMR. Flax delivers different plant lignans and substantial fiber and alpha-linolenic acid (ALA); HMR is chosen when a low-mass, high-efficiency ENL precursor without flax fiber is preferred. Some multi-ingredient women’s formulas combine HMR with hop extracts or other phytoestrogens (e.g., Life Extension–style combinations)—evidence for combinations is weaker than for HMR alone.
* **Time of day:** No strict chronobiology data. Taking with a meal may aid comfort and consistent absorption; once-daily dosing matches the long ENL exposure profile (ENL Cmax near 24 hours after a dose in pharmacokinetic sampling).
* **Half-life and dosing split:** Parent 7-HMR peaks early (~1 hour); enterolactone rises over many hours. Split dosing is optional and not required by published pharmacokinetics (PK); once daily is typical on labels.
* **Genetic polymorphisms:** No validated pharmacogenetic dose algorithm for HMR. Variants affecting estrogen-receptor signaling, sex-hormone metabolism, or microbiome composition could theoretically modify response but are not used clinically for HMR titration.
* **Sex-based differences:** Protocol evidence is postmenopausal female–centric for symptoms; men using HMR for prostate or general lignan support lack dedicated dose-finding trials—same 36–72 mg/day range is commonly marketed.
* **Age:** Older adults are the intended population; no geriatric dose reduction is defined. Frailty, polypharmacy, and low body weight warrant conservative starts (36 mg/day).
* **Baseline biomarkers:** Low baseline enterolactone or very low dietary lignan intake may predict larger ENL increments; measuring ENL is optional and not widely available clinically.
* **Pre-existing conditions:** Hormone-sensitive disease, active liver disease, or recent major antibiotics may justify delay, specialist clearance, or food-based lignans instead.


## Discontinuation & Cycling

* **Duration of use:** Marketed as a daily dietary supplement for ongoing menopausal, general antioxidant, or lignan-support goals rather than a short antibiotic-like course. Human controlled data stop at 8 weeks for symptoms; longer use is common in commerce without formal cycling trials.
* **Withdrawal effects:** No classic withdrawal syndrome is described. Hot flashes or other symptoms may return toward baseline after stopping if the prior benefit was real.
* **Tapering:** Not pharmacologically required; abrupt stop is acceptable. Optional taper (e.g., 72 → 36 mg/day for 1–2 weeks) if psychologically preferred.
* **Cycling:** No evidence that cycling preserves efficacy. Continuous daily use matches ENL steady-state logic; cycling is not required to avoid tolerance based on available data.


## Sourcing and Quality

* **Standardization:** Prefer products listing **HMRlignan** (or equivalent) with a stated milligram amount of 7-hydroxymatairesinol / hydroxymatairesinol potassium acetate and standardization (commonly NLT (not less than) 90% 7-HMR co-crystal). Generic “spruce lignan” without assay is harder to dose.
* **Source material:** Norway spruce (*Picea abies*) knotwood is the established commercial source; responsible forestry and knot selection matter for purity and sustainability claims.
* **Third-party testing:** Look for identity, potency, heavy metals, residual solvents, and microbial limits from manufacturers following ISO (International Organization for Standardization) and GMP (Good Manufacturing Practice) quality systems. Independent ConsumerLab or USP (United States Pharmacopeia) monographs specific to HMR were not identified—rely on brand COAs (certificates of analysis) and reputable suppliers (e.g., Linnea-sourced finished goods).
* **Formulation:** Capsules of the co-crystallized aglycone are standard. Avoid products that hide HMR milligrams inside proprietary blends.
* **Reputable channels:** Established supplement brands that disclose Linnea HMRlignan or equivalent assay (historical examples include certain Life Extension and Swanson spruce-lignan products). Verify current labels, as formulas change.
* **Regulatory status:** United States: dietary supplement ingredient with New Dietary Ingredient history. Europe: novel-food–type authorization pathways have been referenced for hydroxymatairesinol ingredients; local label claims vary. Not an FDA (U.S. Food and Drug Administration)–approved drug for any disease.


## Practical Considerations

* **Time to effect:** Enterolactone and parent 7-HMR rise within days; hot-flash diary changes in the Udani study were assessed over 8 weeks. Expect weeks, not hours, for symptom evaluation.
* **Common pitfalls:** Expecting drug-level hot-flash control comparable to systemic hormone therapy; using sub-therapeutic microdoses in multi-ingredient blends that underdeliver 7-HMR; ignoring microbiome disruption during antibiotics; combining many phytoestrogens without tracking total load; treating HMR as proven cancer therapy.
* **Regulatory status:** Sold as a dietary supplement / novel food ingredient, not as an approved treatment for menopause, cancer, or cardiovascular disease. Disease claims are not permitted on US supplement labels.
* **Cost and access:** Generally moderate cost relative to specialty hormones; widely available online. Price depends on brand and whether HMRlignan is the sole active or part of a blend.


## Interaction with Foundational Habits

* **Sleep:** No direct sedating or stimulating signal is established for HMR. Indirectly, fewer nocturnal hot flashes—if the menopausal benefit replicates—could improve sleep continuity (potentiating, symptom-mediated).
* **Nutrition:** Best viewed as complementary to a lignan- and fiber-rich diet (whole grains, seeds, berries, vegetables). High-fiber, plant-forward patterns support the microbiota that produce enterolactone (potentiating). Extreme low-fiber or repeated antibiotic exposure may blunt conversion (blunting).
* **Exercise:** No evidence that HMR blunts hypertrophy or endurance adaptations. Exercise itself improves menopausal symptom burden and metabolic health; combination is complementary (potentiating for overall cardiometabolic and symptom goals).
* **Stress management:** No direct cortisol data for HMR. Anti-inflammatory and antioxidant mechanisms are theoretical adjuncts to stress-reduction practices, not substitutes (indirect / none proven).


## Monitoring Protocol & Defining Success

Baseline evaluation before extended use typically covers menopausal symptom burden (if relevant), medication list (especially endocrine agents), and general metabolic health. Ongoing monitoring can be light for healthy users at standard doses.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Enterolactone (plasma/serum) | Higher within lab reference often targeted in lignan research; no universal “optimal” clinical cut-off | Confirms conversion of 7-HMR to ENL | Specialty/research test; not routine. Fasting status per lab. Pair with symptom diary if used. |
| Estradiol / FSH (postmenopause) | Age- and goal-dependent; conventional postmenopausal estradiol typically <30 pg/mL | Context for phytoestrogen use and differential of hot flashes | FSH = follicle-stimulating hormone. Not required solely for HMR; useful if hormones are already being managed. Morning draw. |
| High-sensitivity CRP | Often <1.0 mg/L functional target | General inflammatory tone | CRP = C-reactive protein (systemic inflammation marker). Conventional lab reference often <3.0 mg/L (sometimes <10 mg/L by method). Non-specific; optional if tracking anti-inflammatory lifestyle package. |
| Fasting glucose / HbA1c | Glucose ~70–90 mg/dL; HbA1c often <5.5% functional aim | Metabolic context given preclinical HMR data | HbA1c = glycated hemoglobin (average glucose over ~3 months). Conventional fasting glucose often ~70–99 mg/dL; conventional HbA1c non-diabetic range typically <5.7%. Standard fasting labs; not HMR-specific safety labs. |
| Comprehensive metabolic panel (ALT, AST, creatinine, eGFR) | Within lab reference; eGFR ≥90 mL/min/1.73 m² preferred | Baseline organ function before long-term polyphenol supplement | ALT/AST = liver enzymes (alanine/aspartate aminotransferase); eGFR = estimated glomerular filtration rate (kidney function). Conventional ranges apply; recheck if multi-supplement user or comorbidities. |

Baseline testing is optional for healthy adults at 36–72 mg/day but is reasonable when HMR is added to a complex hormone or oncology-adjacent plan: symptom scores, medication review, and basic metabolic panel.

Ongoing monitoring: reassess menopausal symptom diaries at **4 and 8 weeks**, then every **3–6 months** if continued; repeat safety labs every **6–12 months** in long-term multi-supplement users or those with comorbidities. Enterolactone assays, if used, can be repeated after ≥4 weeks on a stable dose.

**Qualitative markers:**

* Hot flash frequency, severity, and night sweats
* Sleep continuity and next-day energy
* Digestive comfort after dosing
* Subjective joint comfort or recovery (exploratory only)
* Overall sense of hormonal stability (libido, mood, cycle regularity if pre-/perimenopausal)


## Emerging Research

* **Independent replication of menopausal efficacy:** The [Udani et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24606716/) single-blind dose study remains the main human symptom trial. Larger, placebo-controlled randomized controlled trials (RCTs) of standardized 7-HMR for vasomotor symptoms (hot flashes and night sweats) would materially strengthen or weaken the clinical case. No dedicated HMR menopausal RCT was identified on ClinicalTrials.gov as of this review.
* **Enterolactone epidemiology vs isolated HMR:** Ongoing and recent meta-analyses continue to refine associations between lignan intake / ENL levels and breast-cancer prognosis ([Liu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33854638/)), phytonutrient post-diagnosis outcomes ([van Die et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38070485/)), and cardiovascular mortality ([Rienks et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28441720/)). These strengthen the ENL hypothesis but do not substitute for HMR-specific trials.
* **Metabolic and body-composition translation:** [Biasiotto et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30105962/) mouse data on weight, fat, and glucose handling invite human metabolic syndrome or obesity pilots that have not yet appeared as registered HMR trials.
* **Neuroprotection:** Rodent Parkinson’s-model work with HMR/lignan ([Giuliano et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31586482/)) is early-stage; human cognitive or neurodegenerative endpoints are untested.
* **Microbiome personalization:** Research mapping which bacterial taxa maximize 7-HMR→ENL conversion could explain response heterogeneity and guide co-interventions (fiber, fermented foods, or live biotherapeutics).
* **Registered interventional trials:** No ClinicalTrials.gov studies specifically of hydroxymatairesinol / HMRlignan as the primary intervention were identified at search time; future NCT entries would be high-value updates.


## Conclusion

HMR lignans are a standardized Norway spruce source of 7-hydroxymatairesinol that the body converts into enterolactone, a mammalian lignan studied for hormone-related and antioxidant pathways. Human evidence is still narrow: a small, manufacturer-supported trial in which participants knew their dose assignment found fewer hot flashes at 72 mg per day over eight weeks, alongside clear rises in blood 7-HMR and enterolactone. That commercial interest in the ingredient funds much of the available human work is a material limitation when weighing confidence in the results. Safety at usual supplemental doses appears favorable in short studies and animal safety work, with only mild, dose-related hormonal signals at much higher animal exposures.

Broader hopes—breast and prostate risk modification, metabolic improvement, cardiovascular protection—rest mainly on enterolactone population studies and laboratory models rather than HMR-specific trials that track disease events. No systematic reviews of HMR itself exist, and major longevity-oriented clinicians have not published dedicated protocols. For health- and longevity-focused adults, HMR is best understood as an efficient, small-dose way to raise enterolactone and a candidate option for postmenopausal hot flashes, not as a proven longevity compound that changes the course of disease. Quality hinges on measured 7-HMR content. Overall evidence quality is preliminary-to-moderate for absorption and how well people tolerate usual doses, and low for clear disease or symptom outcomes beyond one small menopausal study.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**